Selective Cyclooxygenase Inhibitors

David B. Reitz; Karen Seibert

doi:10.1016/S0065-7743(08)60932-X

Selective Cyclooxygenase Inhibitors

David B. Reitz
, Karen Seibert

Department of Anesthesiology

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Abstract

The significant advances made in recent years in the discovery of selective cyclooxygenase inhibitors has been impressive. The current availability of human recombinant COX-1 and COX-2 assays used in determining enzyme selectivity has facilitated the discovery and development of selective COX-2 inhibitors as therapeutic agents for the treatment of inflammation. Since no clinical data has been reported to date, it is unknown whether selective COX-2 inhibitors will have genuine therapeutic utility in the treatment of inflammation without the gastric aide-eff ects associated with non-selective cyclooxygenase inhibitors (NSAIDs).

Original language	English
Pages (from-to)	179-188
Number of pages	10
Journal	Annual Reports in Medicinal Chemistry
Volume	30
Issue number	C
DOIs	https://doi.org/10.1016/S0065-7743(08)60932-X
State	Published - Jan 1 1995

Access to Document

10.1016/S0065-7743(08)60932-X

Cite this

@article{f14e0d7e98594737a7f780ed7151870a,

title = "Selective Cyclooxygenase Inhibitors",

abstract = "The significant advances made in recent years in the discovery of selective cyclooxygenase inhibitors has been impressive. The current availability of human recombinant COX-1 and COX-2 assays used in determining enzyme selectivity has facilitated the discovery and development of selective COX-2 inhibitors as therapeutic agents for the treatment of inflammation. Since no clinical data has been reported to date, it is unknown whether selective COX-2 inhibitors will have genuine therapeutic utility in the treatment of inflammation without the gastric aide-eff ects associated with non-selective cyclooxygenase inhibitors (NSAIDs).",

author = "Reitz, \{David B.\} and Karen Seibert",

year = "1995",

month = jan,

day = "1",

doi = "10.1016/S0065-7743(08)60932-X",

language = "English",

volume = "30",

pages = "179--188",

journal = "Annual Reports in Medicinal Chemistry",

issn = "0065-7743",

number = "C",

}

TY - JOUR

T1 - Selective Cyclooxygenase Inhibitors

AU - Reitz, David B.

AU - Seibert, Karen

PY - 1995/1/1

Y1 - 1995/1/1

N2 - The significant advances made in recent years in the discovery of selective cyclooxygenase inhibitors has been impressive. The current availability of human recombinant COX-1 and COX-2 assays used in determining enzyme selectivity has facilitated the discovery and development of selective COX-2 inhibitors as therapeutic agents for the treatment of inflammation. Since no clinical data has been reported to date, it is unknown whether selective COX-2 inhibitors will have genuine therapeutic utility in the treatment of inflammation without the gastric aide-eff ects associated with non-selective cyclooxygenase inhibitors (NSAIDs).

AB - The significant advances made in recent years in the discovery of selective cyclooxygenase inhibitors has been impressive. The current availability of human recombinant COX-1 and COX-2 assays used in determining enzyme selectivity has facilitated the discovery and development of selective COX-2 inhibitors as therapeutic agents for the treatment of inflammation. Since no clinical data has been reported to date, it is unknown whether selective COX-2 inhibitors will have genuine therapeutic utility in the treatment of inflammation without the gastric aide-eff ects associated with non-selective cyclooxygenase inhibitors (NSAIDs).

UR - https://www.scopus.com/pages/publications/0001650323

U2 - 10.1016/S0065-7743(08)60932-X

DO - 10.1016/S0065-7743(08)60932-X

M3 - Article

AN - SCOPUS:0001650323

SN - 0065-7743

VL - 30

SP - 179

EP - 188

JO - Annual Reports in Medicinal Chemistry

JF - Annual Reports in Medicinal Chemistry

IS - C

ER -

Selective Cyclooxygenase Inhibitors

Abstract

Access to Document

Other files and links

Fingerprint

Cite this